Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shattuck LabsSTTK +4.80%42 5-Day RSI is 64.29 as of Jul. 25, 2026. GuruFocus rates STTK with a GF Score™ of 42/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,420 Biotechnology companies, Shattuck Labs ranks worse than 73.8% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-25), Shattuck Labs's 5-Day RSI is 64.29.
The industry rank for Shattuck Labs's 5-Day RSI or its related term are showing as below:
STTK's 5-Day RSI is ranked worse than 73.8% of 1420
companies
in the Biotechnology industry
Industry Median: 43.095
vs STTK: 64.29
Shattuck Labs (NAS:STTK) 5-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Shattuck Labs 5-Day RSI Related Terms
STTK vs ACHV, CRMD, EIKN: 5-Day RSI Comparison
For the Biotechnology subindustry, Shattuck Labs's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shattuck Labs 5-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shattuck Labs's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Shattuck Labs's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shattuck Labs (STTK) has a 5-Day RSI of 64.29 as of Jul. 25, 2026. According to the industry distribution chart, Shattuck Labs ranks #1048 out of 1420 companies in the Biotechnology industry, placing it in the top 73.8%.
Is Shattuck Labs' 5-Day RSI too high?
Shattuck Labs' current 5-Day RSI is 64.29. The Biotechnology industry median 5-Day RSI is 43.10. Shattuck Labs' value of 64.29 is 49.2% above this industry median. Based on the distribution chart, Shattuck Labs ranks #1048 out of 1420 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shattuck Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shattuck Labs' 5-Day RSI compare to ACHV and CRMD?
According to the Biotechnology industry distribution chart, Shattuck Labs ranks #1048 out of 1420 companies for 5-Day RSI. This places Shattuck Labs in the lower half of its industry. The industry median 5-Day RSI is 43.10. Shattuck Labs' value of 64.29 is 49.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Biotechnology company?
The median 5-Day RSI among Biotechnology companies is 43.10, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shattuck Labs's current 5-Day RSI of 64.29 is 49.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 5-Day RSI is 43.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shattuck Labs's current 5-Day RSI is 64.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shattuck Labs stock overvalued right now?
Based on GuruFocus' analysis, Shattuck Labs (STTK) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $7.42 — trading 606.7% above its estimated fair value. The current 5-Day RSI is 64.29 and 49.2% above the Biotechnology industry median of 43.10. Shattuck Labs' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Shattuck Labs (STTK), the current 5-Day RSI is 64.29 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shattuck Labs (STTK) Overvalued in 2026?
Based on GuruFocus' analysis, Shattuck Labs stock appears to be overvalued.
The current stock price of $7.42 is trading 606.7% above its estimated GF Value™ of $1.05.
GuruFocus considers Shattuck Labs to be Significantly Overvalued.
Key valuation signals for STTK:
5-Day RSI: 64.29
GF Value™: $1.05 vs. price of $7.42 (606.7% above fair value)
Industry Position: 49.2% above the Biotechnology median (#1048 of 1420)
No single metric tells the full story. See the STTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
42GF Score
Get the complete analysis for STTK
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STTK has been successfully added to your 
